Christmas Comes Early - The FCPA Pilot Program Made Permanent

This article will review some of the key highlights outlined by the DOJ and some considerations for compliance professionals. The heat is on life science companies. Since 2013, there have been 25 Foreign Corruption Practices Act (“FCPA”) matters involving life science companies, 13 of which occurred in the last two years. Although life science companies have not been immune to FCPA investigations in the past, the statement of Acting Chief of the U.S. Department of Justice (“DOJ”) Fraud Section, Sandra Moser in August was loud and clear - the DOJ would be increasing its enforcement efforts of healthcare related companies. We reviewed the outcomes of the FCPA Pilot Program (“Pilot Program”) in the September 2017 issue of the Update, examining the benefits of self-disclosure under the program. Now, a year since its inception, the DOJ has announced that the Pilot Program will now be permanent. To Read the Full Story, Subscribe, Download a Sample Issue, or Sign In       Related StoriesLike the Little Drummer Boy, the Beat Goes on as OIG Enforcement Shows Few Signs of Letting UpA Compliance New Year’s Resolution – Assess the Company’s CultureWill Your Whistle Be Heard at Home? 
Source: Policy and Medicine - Category: American Health Authors: Source Type: blogs